Abstract

Objective: Patients with axial spondyloarthritis (axSpA) in clinical remission tapered tumor necrosis factor inhibitor (TNFi) therapy according to a clinical guideline. Over a 2-year follow-up period, we aimed to investigate flare frequency, dose at which flare occurred, type of flare, and predictors thereof.
OriginalsprogDansk
Publikationsdato2022
StatusUdgivet - 2022
BegivenhedEULAR 2022 - Copenhagen
Varighed: 1 jun. 20224 jun. 2022

Konference

KonferenceEULAR 2022
ByCopenhagen
Periode01/06/202204/06/2022

Citationsformater